Targeted =/ narrow

A great deal of nonsense has been written about molecular medicine. This ranges on the one hand from puff pieces claiming that targeted therapeutics will provide the perfect drugs to cure every patient without side effects, all the way to warnings of doom for the industry as markets get sliced into smaller and smaller pieces. Like most such notions based on group-think rather than the hard analytical work, both ideas are simply wrong.

Some of the first targeted cancer therapies, such as Herceptin and Gleevec, have shown complete cures with a single drug will be the exception, even in cancers driven by a specific target, and initial impressive responses may not be durable...